Fubotv earnings beat by $0.10, revenue topped estimates
HONG KONG - Hutchmed (China) Limited (NASDAQ/AIM:HCM; HKEX:13) announced today that during its Annual General Meeting (AGM), all proposed ordinary and special resolutions were passed. The resolutions included the adoption of the audited financial statements for the year ended December 31, 2024, the re-election of directors, and the re-appointment of auditors, among others.
The AGM saw a high level of support for the resolutions, with the votes for adoption of the financial statements and reports of the directors and independent auditors receiving a 99.9863% approval. The re-election of each director was confirmed with substantial majorities, with the lowest approval being 94.5061% for Ms. Edith Shih.
Additionally, shareholders granted a general mandate for the directors to issue additional shares and repurchase shares of the company, with 99.9637% and 99.9180% approval, respectively.
The company’s board of directors, including Dr. Dan Eldar, Dr. Weiguo Su, Mr. Cheng Chig Fung, Johnny, and others, attended the AGM, which was conducted with the assistance of Computershare Investor Services (Jersey) Limited as the scrutineer for the poll.
Hutchmed is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies for cancer and immunological diseases. It has successfully brought several medicines to market in China, with one also approved globally, including in the US, Europe, and Japan.
The AGM’s voting outcomes reflect the shareholders’ confidence in the company’s governance and strategic direction. The resolutions passed are part of Hutchmed’s continued efforts to manage its resources effectively and pursue its commercial and development objectives.
The information reported here is based on a press release statement from Hutchmed (China) Limited.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.